Search: onr:"swepub:oai:DiVA.org:uu-346362" > Cancer vaccine base...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04842naa a2200469 4500 | |
001 | oai:DiVA.org:uu-346362 | |
003 | SwePub | |
008 | 180316s2018 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3463622 URI |
024 | 7 | a https://doi.org/10.1080/2162402X.2017.13972502 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Fotaki, Grammatikiu Uppsala universitet,Science for Life Laboratory, SciLifeLab,Klinisk immunologi4 aut0 (Swepub:uu)grafo260 |
245 | 1 0 | a Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models |
264 | 1 | c 2018 |
338 | a electronic2 rdacarrier | |
520 | a Autologous patient-derived dendritic cells (DCs) modified ex vivo to present tumor-associated antigens (TAAs) are frequently used as cancer vaccines. However, apart from the stringent logistics in producing DCs on a patient basis, accumulating evidence indicate that ex vivo engineered DCs are poor in migration and in fact do not directly present TAA epitopes to naïve T cells in vivo. Instead, it is proposed that bystander host DCs take up material from vaccine-DCs, migrate and subsequently initiate antitumor T-cell responses. We used mouse models to examine the possibility of using pro-inflammatory allogeneic DCs (alloDCs) to activate host DCs and enable them to promote antigen-specific T-cell immunity. We found that alloDCs were able to initiate host DC activation and migration to draining lymph node leading to T-cell activation. The pro-inflammatory milieu created by alloDCs also led to recruitment of NK cells and neutrophils at the site of injection. Vaccination with alloDCs combined with Ad5M(gp100), an infection-enhanced adenovirus encoding the human melanoma-associated antigen gp100 resulted in generation of CD8+ T cells with a T-cell receptor (TCR) specific for the gp10025-33 epitope (gp100-TCR+). Ad5M(gp100)-alloDC vaccination in combination with transfer of gp100-specific pmel-1 T cells resulted in prolonged survival of B16-F10 melanoma-bearing mice and altered the composition of the tumor microenvironment (TME). We hereby propose that alloDCs together with TAA- or neoepitope-encoding Ad5M can become an “off-the-shelf” cancer vaccine, which can reverse the TME-induced immunosuppression and induce host cellular anti-tumor immune responses in patients without the need of a time-consuming preparation step of autologous DCs. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Immunologi inom det medicinska området0 (SwePub)301102 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Immunology in the medical area0 (SwePub)301102 hsv//eng |
653 | a adjuvants | |
653 | a Allogeneic dendritic cells | |
653 | a cell-based immunotherapy | |
653 | a tumor microenvironment | |
653 | a tumor-associated antigen | |
700 | 1 | a Jin, Chuan,d 1986-u Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:uu)chuji162 |
700 | 1 | a Kerzeli, Iliana Kyriakiu Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:uu)iliky579 |
700 | 1 | a Ramachandran, Mohanraj,d 1988-u Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:uu)mohra272 |
700 | 1 | a Martikainen, Minttu-Mariau Uppsala universitet,Institutionen för immunologi, genetik och patologi,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:uu)minma327 |
700 | 1 | a Karlsson-Parra, Alexu Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab,Immunicum AB, Gothenburg4 aut0 (Swepub:uu)aka12694 |
700 | 1 | a Yu, Di,d 1985-u Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:uu)diayu422 |
700 | 1 | a Essand, Magnusu Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:uu)magnessa |
710 | 2 | a Uppsala universitetb Science for Life Laboratory, SciLifeLab4 org |
773 | 0 | t Oncoimmunologyg 7:3q 7:3x 2162-4011x 2162-402X |
856 | 4 | u https://doi.org/10.1080/2162402X.2017.1397250y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1191184/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-346362 |
856 | 4 8 | u https://doi.org/10.1080/2162402X.2017.1397250 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.